Dr SONNTAG Cécile

Fiche personne

Coordonnées

ICANS
17 rue Albert Calmette
67200 STRASBOURG

03 68 76 66 66

Territoire

Alsace

Statut

Hospitalier

Affiliation

Institut de cancérologie Strasbourg Europe (ICANS)

Recherche

Expertises :
- Clinique:Hématologie

Publications

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Moreau P, Hulin C, Talbot A, Demarquette H, Caillot L, Chalopin T, Bobin A, Manier S, Leleu X, Karlin L, Caillot D, Sonntag C, Feugier P, Roussel M, Gounot R, Macro M, Mohty M, Garderet L, Tiab M, Orsini-Piocelle F, Vincent L, Meuleman N, Fontan J, Montes L, Vekemans MC, Escoffre-Barbe M, Eveillard JR, Schiano de Colella JM, Lambert J, Mary JY, Fermand JP, Arnulf B, Corre J, Avet-Loiseau H, Facon T, Harousseau JL, Touzeau C, Perrot A

Blood Cancer J. 2025 10 24;15(1):177

Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study.

Chalopin T, Cellerin E, Demarquette H, Pieragostini A, Sonntag C, Jaquet C, De Wyngaert Z, Rumpler A, Roussel M, Labouré G, Morel V, Vincent L, Salle V, Cazaubiel T, Bobin A, Schavgoulidze A, Corre J, Leleu X, Manier S

Blood Cancer J. 2025 10 21;15(1):174

Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study.

Cazaubiel T, Decaux O, Royer B, Caillot D, Bobin A, Belhadj-Merzoug K, Macro M, Vincent L, Perrot A, Mohty M, Karlin L, Jacquet C, Frenzel L, Chalopin T, Sonntag C, Fontan J, Rigaudeau S, Touzeau C, Demarquette H, Chaib A, Santana C, Darre S, Bareau B, Garlantézec R, Hulin C

Clin Hematol Int. 2025 09 18;7(3):60-68

Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study.

Chalopin T, Hulin C, Royer B, Bastie JN, Bobin A, Merzoug KB, Macro M, Karlin L, Jacquet C, Mohty M, Frenzel L, Sonntag C, Fontan J, Rigaudeau S, Roussel M, Sanhes L, Chaoui D, Vincent L, Orfeuvre H, Bouketouche M, Garlantezec R, Decaux O, Perrot A

Haematologica. 2025 08 28;:

The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study.

Chalopin T, Decaux O, Hulin C, Perrot A, Macro M, Royer B, Bastie JN, Bobin A, Jacquet C, Mohty M, Frenzel L, Sonntag C, Roussel M, Sanhes L, Chaoui D, Dib M, Slama B, Richez V, Montes L, Dervite I, Laribi K, Re D, Garlantezec R, Merzoug KB, Vincent L

Clin Lymphoma Myeloma Leuk. 2025 07 24;:

Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020.

Vincent L, Decaux O, Perrot A, Royer B, Chalopin T, Bobin A, Macro M, Caillot D, Karlin L, Jacquet C, Sonntag C, Mohty M, Frenzel L, Jaccard A, Manier S, Sanhes L, Chaoui D, Moreau P, Garlantézec R, Texier N, Louni C, Maarouf Z, Loiseau HA, Hulin C, Merzoug KB

Cancer Med. 2025 03;14(6):e70619

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial.

Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre-Barbe M, Gay J, Chalopin T, Gounot R, Schiano de Colella JM, Tiab M, Mohty M, Kuhnowski F, Fontan J, Manier S, Orsini Piocelle F, Vincent L, Rigaudeau S, Leleu X, Hébraud B, Flet L, Malfuson JV, Jacquet C, Chaoui D, Meuleman N, Abarah W, Montes L, Benramdane R, Sonntag C, Zerazhi H, Danu A, Allangba O, Dib M, Roussel M, Cereja S, Depaus J, Branche N, Demarquette H, Richez V, Bruiec C, Frenzel L, Vekemans MM, Bigot N, Avet-Loiseau H, Corre J, Moreau P

Blood. 2025 01 22;:

Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse.

Touzeau C, Leleu X, Tiab M, Macro M, Perrot A, Gay J, Chateleix C, Moreau S, Karlin L, Jacquet C, Manier S, Hulin C, Decaux O, Richez V, Chalopin T, Mohty M, Orsini-Piocelle F, Caillot D, Sonntag C, Vignon M, Bobin A, Avet-Loiseau H, Jobert A, Planche L, Corre J, Moreau P

Br J Haematol. 2025 01 5;:

Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study.

Bobin A, Manier S, De Keizer J, Srimani JK, Hulin C, Karlin L, Caillot D, Lafon I, Mariette C, Araujo C, Arnulf B, Bareau B, Belhadj K, Benboubker L, Braun T, Calmettes C, Decaux O, Dib M, Demarquette H, Jacquet C, Sonntag C, Godet S, Jaccard A, Lenain P, Macro M, Richez-Olivier V, Tiab M, Vincent L, Zerazhi H, Pétillon MO, Rollet S, Gardeney H, Durand G, Levy A, Touzeau C, Perrot A, Moreau P, Facon T, Corre J, Ragot S, Avet-Loiseau H, Leleu X

Haematologica. 2024 11 14;:

The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge.

Decaux O, Garlantézec R, Belhadj-Merzoug K, Macro M, Frenzel L, Perrot A, Moreau P, Royer B, Caillot D, Leleu X, Mohty M, Karlin L, Feugier P, Rigaudeau S, Fontan J, Sonntag C, Vincent L, Chalopin T, Avet Loiseau H, Maarouf Z, Chanaz L, Texier N, Hulin C

Clin Hematol Int. 2024 07 23;6(3):22-27

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 tria

Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Zweegman S, Caillon H, Caillot D, Avet-Loiseau H, Delforge M, Dejoie T, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Schiano de Colella JM, van de Donk NW, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Hua W, Wang J, Tuozzo A, de Boer C, Rowe M, Vanquickelberghe V, Carson R, Vermeulen J, Corre J, Sonneveld P,

Lancet Oncol. 2024 06 14;:

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study on the behalf of G2I and IFM.

Jourdes A, Cellerin E, Touzeau C, Harel S, Denis B, Escure G, Faure E, Jamard S, Danion F, Sonntag C, Ader F, Karlin L, Soueges S, Cazelles C, de La Porte des Vaux C, Frenzel L, Lanternier F, Brousse X, Cazaubiel T, Berger P, Collignon A, Blot M, Pieragostini A, Charles M, Chaleteix C, Redor A, Roland V, Cartau T, Macro M, Chalopin T, Vallet N, Perrot A, Martin-Blondel G,

Clin Microbiol Infect. 2024 03 1;:

Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients.

Schavgoulidze A, Lauwers-Cances V, Perrot A, Cazaubiel T, Chretien ML, Moreau P, Facon T, Leleu X, Karlin L, Stoppa AM, Decaux O, Belhadj K, Arnulf B, Mohty M, Ariette CM, Fohrer-Sonntag C, Lenain P, Marolleau JP, Tiab M, Araujo C, Orsini-Piocelle F, Jaccard A, Roussel M, Benboubker L, Eveillard JR, Dib M, Divoux M, Attal M, Avet-Loiseau H, Corre J

Haematologica. 2022 09 29;:

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label,

Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Béné MC, Zweegman S, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Stoppa AM, van de Donk NWCJ, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Krevvata M, Zhang K, de Boer C, Vara S, Kampfenkel T, Vanquickelberghe V, Vermeulen J, Avet-Loiseau H, Sonneveld P

Lancet Oncol. 2021 Sep 13;:

Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results.

Roussel M, Lauwers-Cances V, Wuilleme S, Belhadj K, Manier S, Garderet L, Escoffre-Barbe M, Mariette S, Benboubker L, Caillot D, Sonntag C, Touzeau C, Dupuis J, Moreau P, Leleu X, Facon T, Hébraud B, Corre J, Attal M

Blood. 2021 Apr 7;:

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P

Lancet. 2019 Jun 3;: